Ocular Therapeutix Clears FDA Hurdle for Wet AMD Drug AXPAXLI — Ocular Therapeutix, Inc.

Event summary

Ocular Therapeutix completed a positive Pre-NDA meeting with the FDA for AXPAXLI in wet AMD, confirming plans for a 4Q 2026 NDA submission.
NDA will include Week 52 efficacy and safety data from SOL-1 trial, interim SOL-R safety data, and confirmatory evidence.
AXPAXLI aims to be the first TKI approved for wet AMD, leveraging a 505(b)(2) pathway that could shorten FDA review by up to 60 days.
Company accelerates commercial readiness ahead of a potential 2027 launch.

The big picture

Ocular Therapeutix’s positive Pre-NDA meeting for AXPAXLI aligns with its strategy to disrupt the wet AMD treatment landscape, which currently faces challenges with pulsatile injections and high discontinuation rates. The company’s focus on durability and sustained disease control positions AXPAXLI as a potential game-changer, provided it secures FDA approval and navigates commercialization effectively. The wet AMD market, affecting millions globally, represents a significant opportunity for Ocular Therapeutix to establish AXPAXLI as a first-in-class therapy.

What we're watching

Regulatory Efficiency: Whether the 505(b)(2) pathway will deliver the expected 60-day review acceleration for AXPAXLI.
Market Positioning: How AXPAXLI’s potential approval as the first TKI for wet AMD will impact competitive dynamics.
Commercial Execution: The pace at which Ocular Therapeutix can scale commercial operations for a 2027 launch.